Chris Polman: quietly making multiple sclerosis research tick.

Autor: Holmes D

Publikováno v: The Lancet. Neurology [Lancet Neurol] 2011 Oct; Vol. 10 (10), pp. 876.

Book Review Multiple Sclerosis: Clinical challenges and controversies Edited by Alan J. Thompson, Chris Polman, and Reinhard Hohlfeld. 360 pp., illustrated. London, Martin Dunitz, 1997. (Distributed by Mosby, St. Louis.) $99.50. 1-85317-428-9

Autor: Michael Ronthal

Publikováno v: New England Journal of Medicine. 338:630-630

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::988b56e4a52d87968869a8741f0f7d02
https://doi.org/10.1056/nejm199802263380922

Quantifying progression of multiple sclerosis via classification of depth videos

Autor: Peter, Kontschieder, Jonas F, Dorn, Cecily, Morrison, Robert, Corish, Darko, Zikic, Abigail, Sellen, Marcus, D'Souza, Christian P, Kamm, Jessica, Burggraaff, Prejaas, Tewarie, Thomas, Vogel, Michela, Azzarito, Ben, Glocker, Peter, Chin, Frank, Dahlke, Chris, Polman, Ludwig, Kappos, Bernard, Uitdehaag, Antonio, Criminisi

Publikováno v: Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention. 17(Pt 2)

This paper presents new learning-based techniques for measuring disease progression in Multiple Sclerosis (MS) patients. Our system aims to augment conventional neurological examinations by adding quantitative evidence of disease progression. An off-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6c99d9bef0abe401737c83dc07ea9563
https://pubmed.ncbi.nlm.nih.gov/25485408

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

Autor: Chris, Polman, Ludwig, Kappos, Mark S, Freedman, Gilles, Edan, Hans-Peter, Hartung, David H, Miller, Xavier, Montalbán, Frederick, Barkhof, Krzysztof, Selmaj, Bernard M J, Uitdehaag, Susanne, Dahms, Lars, Bauer, Christoph, Pohl, Rupert, Sandbrink, S, Howell

Publikováno v: Journal of neurology, Vol. 255, no.4, p. 480-7 (2008)
Journal of Neurology, 255(4), 480-487. D. Steinkopff-Verlag
Polman, C, Kappos, L, Freedman, M, Edan, G, Hartung, H P, Miller, D H, Montalbán, X, Barkhof, F, Selmaj, K, Uitdehaag, B, Dahms, S, Bauer, L, Pohl, C & Sandbrink, R 2007, ' Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b ', Journal of Neurology .
Journal of Neurology. D. Steinkopff-Verlag
Polman, C H, Kappos, L, Freedman, M S, Edan, G, Hartung, H P, Miller, D H, Montalban, X, Barkhof, F, Selmaj, K, Uitdehaag, B M J, Dahms, S, Bauer, L, Pohl, C & Sandbrink, R 2008, ' Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b ', Journal of Neurology, vol. 255, no. 4, pp. 480-487 . https://doi.org/10.1007/s00415-007-0733-2

BACKGROUND : The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions. METHODS : Subgroups of 468 patients (IFNB-1b: n = 292; placebo: n = 176)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e80cda843df17a9d368fc9d69af95b42
https://pubmed.ncbi.nlm.nih.gov/18004635

Hans van Goudoever. (Dutch/Flemish)

Autor: Kiers, Bart

Publikováno v: Zorgvisie; Feb2024, Vol. 54 Issue 1, p10-16, 7p